1. 1250PEstimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. (23rd October 2018) Authors: Dummer, R; Schadendorf, D; Hauschild, A; Santinami, M; Atkinson, V G; Mandala, M; Chiarion Sileni, V; Larkin, J; Nyakas, M S; Dutriaux, C; Haydon, A; Mortier, L; Robert, C; Schachter, J; Feng, X; de Jong, E; Mookerjee, B; Kefford, R; Kirkwood, J M; Long, G V Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1251PAdverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. (23rd October 2018) Authors: Atkinson, V G; Hauschild, A; Santinami, M; Mandala, M; Chiarion Sileni, V; Larkin, J; Nyakas, M S; Dutriaux, C; Haydon, A; Mortier, L; Robert, C; Schachter, J; Schadendorf, D; Feng, X; de Jong, E; Mookerjee, B; Kefford, R; Dummer, R; Kirkwood, J M; Long, G V Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1560PDMajor determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey. (23rd October 2018) Authors: Kandolf Sekulovic, L O; Agarwala, S S; Hauschild, A; Guo, J; McArthur, G A; Lorigan, P; Cinat, G; Caglevich, C; Lebbe, C; Rutkowski, P L; Gogas, H; Dummer, R; Neyns, B; Bastholt, L; Wainstein, A; Herceg, D; Banjin, M; Zhukavets, A; Ocvirk, J; Garbe, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 97P Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti–PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC). (15th December 2019) Authors: Rischin, D; Khushalani, N I; Schmults, C D; Guminski, A; Chang, A L S; Lewis, K D; Lim, A M; Hernandez-Aya, L; Hughes, B G M; Schadendorf, D; Hauschild, A; Stankevich, E; Booth, J; Li, S; Chen, Z; Desai, J; Lowy, I; Fury, M G; Migden, M R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (13th August 2019) Authors: Long, G V; Flaherty, K T; Stroyakovskiy, D; Gogas, H; Levchenko, E; de Braud, F; Larkin, J; Garbe, C; Jouary, T; Hauschild, A; Chiarion-Sileni, V; Lebbe, C; Mandalá, M; Millward, M; Arance, A; Bondarenko, I; Haanen, J B A G; Hansson, J; Utikal, J; Ferraresi, V Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1848 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗